REPARE THERAPEUTICS INC (RPTX)
US7602731025 - Common Stock
Which stocks are moving on Friday?
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Top movers in Friday's session
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
Why Is Repare Therapeutics Stock Trading Lower On Friday?
On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial. Across all tumor types treated at the optimized RP2D (n=67),
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Top movers in Friday's pre-market session
Discover the top movers in Friday's pre-market session and stay informed about market dynamics.
These stocks are moving in today's after hours session
Stay updated with the stocks that are on the move in today's after-hours session.
Wednesday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund
/CNW/ - Alberta Enterprise Corporation (AEC) announced today that it has invested US$7.5 million into Amplitude Ventures' US$192-million Fund II to give early...
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Amplitude Ventures Closes $263 Million Precision Medicine Venture Fund
/CNW/ - Amplitude Ventures, a full-stack venture capital firm focused on investing in precision medicine at the intersection of biology and AI, today announced...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're diving into the biggest pre-market stock movers for Wednesday will a look at all of the latest news happening this morning.
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
RPTX stock results show that Repare Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Repare Therapeutics (NASDAQ:RPTX) just reported results for the first quarter o...
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
